[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FR2826278B1 - Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant - Google Patents

Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant

Info

Publication number
FR2826278B1
FR2826278B1 FR0108130A FR0108130A FR2826278B1 FR 2826278 B1 FR2826278 B1 FR 2826278B1 FR 0108130 A FR0108130 A FR 0108130A FR 0108130 A FR0108130 A FR 0108130A FR 2826278 B1 FR2826278 B1 FR 2826278B1
Authority
FR
France
Prior art keywords
medicament
manufacturing
antidiabetic agents
healing effect
antidiabetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0108130A
Other languages
English (en)
Other versions
FR2826278A1 (fr
Inventor
Philippe Briet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sante SAS
Original Assignee
LIPHA SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0108130A priority Critical patent/FR2826278B1/fr
Application filed by LIPHA SAS filed Critical LIPHA SAS
Priority to AT02748965T priority patent/ATE346601T1/de
Priority to AU2002319381A priority patent/AU2002319381A1/en
Priority to DK02748965T priority patent/DK1397124T3/da
Priority to PCT/FR2002/002124 priority patent/WO2003003971A2/fr
Priority to US10/479,615 priority patent/US20040147430A1/en
Priority to ES02748965T priority patent/ES2275889T3/es
Priority to EP02748965A priority patent/EP1397124B1/fr
Priority to PT02748965T priority patent/PT1397124E/pt
Priority to DE60216453T priority patent/DE60216453T2/de
Publication of FR2826278A1 publication Critical patent/FR2826278A1/fr
Application granted granted Critical
Publication of FR2826278B1 publication Critical patent/FR2826278B1/fr
Priority to CY20061101738T priority patent/CY1105822T1/el
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
FR0108130A 2001-06-02 2001-06-20 Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant Expired - Fee Related FR2826278B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR0108130A FR2826278B1 (fr) 2001-06-20 2001-06-20 Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant
PT02748965T PT1397124E (pt) 2001-06-20 2002-06-19 Utilização de agentes anti-diabéticos para fabricar um medicamento com efeito cicatrizante
DK02748965T DK1397124T3 (da) 2001-06-20 2002-06-19 Anvendelse af diabetesmidler til fremstilling af et lægemiddel med helende virkning
PCT/FR2002/002124 WO2003003971A2 (fr) 2001-06-20 2002-06-19 Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant
US10/479,615 US20040147430A1 (en) 2001-06-02 2002-06-19 Use of antidiabetics for making a medicine with cicatrizing effect
ES02748965T ES2275889T3 (es) 2001-06-20 2002-06-19 Utilizacion de agentes antidiabeticos para fabricar un medicamento que tiene un efecto cicatrizante.
AT02748965T ATE346601T1 (de) 2001-06-20 2002-06-19 Verwendung von antidiabetika zur herstellung eines vernarbungsfördernden arzneimittels
AU2002319381A AU2002319381A1 (en) 2001-06-20 2002-06-19 Use of antidiabetics for making a medicine with cicatrizing effect
DE60216453T DE60216453T2 (de) 2001-06-20 2002-06-19 Verwendung von antidiabetika zur herstellung eines vernarbungsfördernden arzneimittels
EP02748965A EP1397124B1 (fr) 2001-06-20 2002-06-19 Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant
CY20061101738T CY1105822T1 (el) 2001-06-20 2006-12-04 Χρηση αντιδιαβητικων παραγοντων για την κατασκευη ενος φαρμακου που εχει επουλωτικη δραση

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0108130A FR2826278B1 (fr) 2001-06-20 2001-06-20 Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant

Publications (2)

Publication Number Publication Date
FR2826278A1 FR2826278A1 (fr) 2002-12-27
FR2826278B1 true FR2826278B1 (fr) 2005-03-25

Family

ID=8864566

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0108130A Expired - Fee Related FR2826278B1 (fr) 2001-06-02 2001-06-20 Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant

Country Status (3)

Country Link
US (1) US20040147430A1 (fr)
FR (1) FR2826278B1 (fr)
PT (1) PT1397124E (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2566098A1 (fr) * 2004-05-11 2005-11-17 Santen Pharmaceutical Co., Ltd. Agent therapeutique pour une affection de keratoconjonctivite

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3072527A (en) * 1959-07-01 1963-01-08 Horner Frank W Ltd Use of tolbutamide in the treatment of acne
US3663716A (en) * 1970-06-22 1972-05-16 Miles Lab Method of treating acne with benzyl alcohol
DE2401450A1 (de) * 1973-01-16 1974-07-18 John James Voorhees Pharmazeutische zusammensetzung zur linderung von hautproliferationserkrankungen
US4131652A (en) * 1977-06-22 1978-12-26 Deluccia Charles R Medicinal skin cream for psoriasis and method
US5145679A (en) * 1989-10-05 1992-09-08 Hinson Joan B Topical emollient for prevention and treatment of circulatory induced lesions
AU2905092A (en) * 1991-10-28 1993-06-07 Cytoven Pharmaceutical dipeptide compositions and methods of use thereof
US5629345A (en) * 1993-07-23 1997-05-13 Vide Pharmaceuticals Methods and compositions for ATP-sensitive K+ channel inhibition for lowering intraocular pressure
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
US5597808A (en) * 1995-06-07 1997-01-28 Osteoarthritis Sciences, Incorporated Use of pseudopterosins for promoting wound healing
FR2749583B1 (fr) * 1996-06-07 1998-08-21 Lipha Nouveaux derives de thiazolidine -2,4- dione substitues, leurs procedes d'obtention et les compositions pharmaceutiques en renfermant
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
GB9701374D0 (en) * 1997-01-23 1997-03-12 Univ Liverpool Purinergic agonists and antagonists
US5861149A (en) * 1997-06-04 1999-01-19 Polyheal Ltd. Methods for wound treatment
US5929055A (en) * 1997-06-23 1999-07-27 The Research Foundation Of State University Of New York Therapeutic method for management of diabetes mellitus
JP2000212191A (ja) * 1999-01-26 2000-08-02 Sankyo Co Ltd リン酸誘導体
CO5200844A1 (es) * 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
FR2802814B1 (fr) * 1999-12-23 2002-02-22 Aventis Pharma Sa Association de deoxyfructosazine et d'un antidiabetique de la famille des sulfonylurees
JP2003530156A (ja) * 2000-04-06 2003-10-14 ユニバーシティ ライセンス ホールディングス インコーポレイテッド 創傷治癒を促進するための組成物および方法

Also Published As

Publication number Publication date
US20040147430A1 (en) 2004-07-29
FR2826278A1 (fr) 2002-12-27
PT1397124E (pt) 2007-01-31

Similar Documents

Publication Publication Date Title
CY2009013I2 (el) Νεα χρηση μιας ενωσης πεπτιδικης κατηγοριας για τη θεραπεια του μη νευροπαθους φλεγμονωδους πονου
ITMI20011083A0 (it) Dispositivo per l'igiene dentale
FR2832637B1 (fr) Utilisation d'un antioxydant pour la fabrication d'un medicament destine au traitement des affections oculaires de surface
ITVR20010019A0 (it) "contrafforte per calzature"
PL370563A1 (en) Deuterated substituted pyrazolylbenzylsulfonamides and medicaments comprising said compounds
FR2809310B1 (fr) Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant
HUP0400222A3 (en) Composition comprising a pde-4 inhibitor and h1-receptor antagonist and the use thereof for the manufacture of a medicament for the treatment of respiratory diseases
FR2826232B1 (fr) Releveur d'epis pour systemes de fauchage de machines de recolte
FR2820875B1 (fr) Structure d'inductance integree
FR2810547B1 (fr) Utilisation d'acides en c2-c10 pour la prevention des infections a bacteries a gram negatif
EP1537875A4 (fr) Medicament preventif/curatif pour l'arteriosclerose
FR2826278B1 (fr) Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant
IT1313383B1 (it) Struttura efficiente di integratore a capacita' commutate integrato
NO20003799D0 (no) Innkorporering av kolesterol-senkende midler i konfektdosisformer
EE200300434A (et) Farmatseutiliselt toimivate ühendite kasutamine
FR2813530B1 (fr) Utilisation du diclofenac pour la fabrication d'un medicament topique pour traiter les brulures
FR2825714B1 (fr) Nouvelle utilisation de complexes d'inclusion de cyclodestrine
FR2837708B1 (fr) Utilisation de la 8'-hydroxydihydroergotamine pour la fabrication d'un medicament contre la migraine
NO20040866L (no) Ny oral forlenget frigivelses doseringsform
FR2830025B1 (fr) Textile d'entretien
UA5606S (uk) Упаковка медичного препарату «кратал»
FR2832032B1 (fr) Bavoir jetable d'un nouveau type
UA4666S (uk) Упаковка медичного препарату «фебриборин»
ITBO990233A0 (it) Apparecchiatura per l' applicazione di una banda sul profilo periferic o circolare di un articolo .
FR2858557B1 (fr) Utilisation d'un peptide zkw pour la preparation d'un medicament inhibiteur de l'agregation plaquettaire

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20090228